-52.6%
RBLX vs GSK
+14.9%
-67.6%
-66.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +8.5% | +5.0% | +3.5% | +8.7% |
| 7D | -7.5% | +4.9% | -12.4% | -7.3% |
| 30D | +10.6% | +9.9% | +0.7% | +11.5% |
| 3M | +33.3% | +0.2% | +33.1% | +32.6% |
| 6M | +3.7% | +2.3% | +1.3% | +3.7% |
| YTD | -39.1% | +7.1% | -46.2% | -34.8% |
| 1Y | -52.6% | +13.1% | -65.8% | -48.6% |
| All | -52.6% | +14.9% | -67.6% | -48.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling